The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

The FDA issues a warning letter to Sanofi over manufacturing violations at its Massachusetts site, citing contamination and ...

French multinational pharmaceutical and healthcare firm Sanofi has completed a £1.4 billion buy-in for its pension scheme.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans for a 5 billion euro ($5.5 billion) share buyback program in 2025. The ...

Sanofi SAN1.73%increase; green up pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...